Alnylam Pharmaceuticals (ALNY) 2024 Wells Fargo Healthcare Conference summary

Key clinical data and market positioning

• Recent ESC data for Vutrisiran in cardiomyopathy was well received, showing a 31% reduction in all-cause mortality at 33–36 months and 36% at 42 months, with strong efficacy even in patients on background therapies.

• Consistent benefits were observed across subgroups, including those on baseline Tafamidis, and a 65% mortality reduction in milder patients (BNP <2,000).

• The market opportunity is significant, with an estimated 200,000–300,000 patients and only a 20% current treatment rate.

• Early switch demand is expected from patients inadequately responding to Tafamidis, supported by prior early access program uptake.

• Combination therapy is unlikely to be a major driver until Tafamidis goes generic (expected end of 2028), after which combo potential increases.

Commercial launch, access, and pricing

• Launch is targeted for Q2 2025, with a regulatory filing expected 3–4 months after top-line data and a six-month FDA review using a Priority Review Voucher.

• Vutrisiran will be a Medicare Part B drug, offering most patients lower or zero out-of-pocket costs compared to Part D drugs, and is less exposed to payer management pressures intensified by IRA changes.

• Drug administration is flexible: 25% of patients receive it at home, 25% at infusion clinics, and 50% in hospital outpatient settings, supporting high compliance rates above 90%.

• There will be a single price for both polyneuropathy and cardiomyopathy indications, with pricing strategy focused on value and patient access; specifics to be shared closer to launch.

Competitive landscape and pipeline outlook

• Vutrisiran is expected to have an 18–24 month lead over competitors if rival studies run to full completion, with ongoing plans to generate additional supporting data.

• Next-generation ALN-TTRsc04 shows >90% knockdown at six months and could offer annual or biannual dosing, with no Sanofi royalty burden and IP protection into the 2040s.

• The company is leveraging existing infrastructure for launch, supporting profitability and operating leverage, and expects to achieve 40% revenue CAGR and non-GAAP operating profitability by end of 2025.

• Broader pipeline includes a phase 2 hypertension program with Roche, a CNS program with Regeneron, and plans to expand into muscle and adipose tissues by end of next year.